Identity and research context
Ipamorelin is a synthetic pentapeptide investigated as a growth hormone secretagogue. Its defining primary report is Raun et al. (1998). The paper concerns experimental endocrine responses, not a catalog-specific formulation.
Primary experimental systems
Raun and colleagues studied rat pituitary cells, rats and conscious swine. They measured growth-hormone responses and compared endocrine selectivity with other secretagogues and growth-hormone-releasing hormone. These model and comparator details are necessary to interpret the report.
What selectivity does and does not mean
In the swine experiments, the tested ACTH and cortisol responses to ipamorelin did not differ significantly from the growth-hormone-releasing hormone comparator. That is a result within the tested experimental conditions, not a guarantee that cortisol or other hormones are unaffected in every species, exposure or person.
Limits for the prepared 5 mg product
The source does not establish a human treatment benefit, a dosing protocol, or the identity and purity of the prepared 5 mg product. Literature on the molecule and exact current product/lot evidence must be reviewed separately.
Related
- ipamorelin 5mgproduct
References
- Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. [primary; rat pituitary cells, rats and conscious swine]PMID: 9849822DOI: 10.1530/eje.0.1390552
More questions?
Ask our Support Team — they can answer follow-up questions about this topic, COAs, storage, or anything else in the research library.
Tap the "Chat with us" tab on the right edge of any page.